{
    "clinical_study": {
        "@rank": "136175", 
        "arm_group": [
            {
                "arm_group_label": "Peg-IFN\u03b1-2a monotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive 180ug peg-IFN\u03b1-2a therapy for 72 weeks, and then followed to 96 weeks."
            }, 
            {
                "arm_group_label": "Sequential therapy", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive entecavir monotherapy for 12 weeks, and 180ug peg-IFN\u03b1-2a therapy is added for the following 12 weeks. After that, entecavir will be stopped and 180ug peg-IFN\u03b1-2a monotherapy for the following 48 weeks. All participants will followed to 96 weeks."
            }, 
            {
                "arm_group_label": "Combination therapy", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive 180ug peg-IFN\u03b1-2a combined with entecavir therapy for 72 weeks, and then followed to 96 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Currently, seven medications are approved for the treatment of hepatitis B: two formulations\n      of interferon and five nucleos(t)ide analogues. The current treatment strategy of chronic\n      hepatitis B is now standard: initial selection of entecavir, tenofovir, or peginterferon\n      alfa-2a (peg-IFN\u03b1-2a). Interferon is administered for a finite duration while nucleotide\n      analogues are usually administered for many years. But among hepatitis B e antigen \uff08HBeAg\uff09\n      positive patients with high serum hepatitis B virus DNA levels, the rates of virological\n      response are poor. And antiviral drug resistance is a major limiting factor to the success\n      of nucleotide analogue treatment. Therefore, combination therapy using peginterferon with an\n      oral agent with a high genetic barrier to resistance might be superior to standard current\n      monotherapy. However, the addition of lamivudine to peg-IFN\u03b1-2a therapy led to a greater\n      decrease in serum HBV DNA levels during treatment but did not increase the rate of HBeAg\n      sero\u00acconversion. Entecavir is a nucleoside analogue superior to lamivudine and adefovir in\n      achieving higher virological response, histological improvement and normalisation of ALT.\n      Moreover, Entecavir has a high genetic barrier with a very low incidence of drug resistance.\n      This study is aimed to investigate the efficacy of combination or sequential therapy using\n      peg-IFN\u03b1-2a and entecavir in HBeAg-positive chronic hepatitis B(CHB) patients."
        }, 
        "brief_title": "Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age\u226516 years\n\n          2. HBsAg positive for more than 6 months, and HBeAg detection is positive for two times\n             in 6 months before enrollment\n\n          3. Serum HBVDNA \uff1e2\u00d710^4IU/ml\n\n          4. 80U/L < serum ALT < 400U/L, and TBIL < 34 umol/L\n\n          5. Serum ALT < 80U/L, but hepatic inflammation scores \u2265 G2 or hepatic fibrosis stage \u2265\n             S3\n\n        Exclusion Criteria:\n\n          1. Co-infected with HCV, HDV or HIV, or autoimmune liver diseases combined\n\n          2. Hepatic decompensation\n\n          3. received antiviral therapy or immunosuppressant drugs before 6 months prior to\n             enrollment\n\n          4. Blood routine examination: WBC \uff1c3\u00d710^9/L\uff0cneutrophile granulocyte \uff1c 1.5\u00d710^9/L\uff0cPLT\n             \uff1c80\u00d710^9/L\n\n          5. Renal function: creatinine \uff1e1.5 times of upper normal limit\n\n          6. Alcoholism or a history of addiction and abuse\n\n          7. Combined with hepatocarcinoma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01906580", 
            "org_study_id": "2011030D"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Peg-IFN\u03b1-2a monotherapy", 
                    "Sequential therapy", 
                    "Combination therapy"
                ], 
                "description": "180ug peg-IFN\u03b1-2a, subcutaneous injection per week", 
                "intervention_name": "Peg-IFN\u03b1-2a", 
                "intervention_type": "Drug", 
                "other_name": "peginterferon alfa-2a"
            }, 
            {
                "arm_group_label": [
                    "Sequential therapy", 
                    "Combination therapy"
                ], 
                "description": "0.5mg,oral administration every day", 
                "intervention_name": "Entecavir", 
                "intervention_type": "Drug", 
                "other_name": "Baraclude"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Peginterferon alfa-2a", 
                "Interferon-alpha", 
                "Entecavir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HBV", 
            "entecavir", 
            "peginterferon"
        ], 
        "lastchanged_date": "July 21, 2013", 
        "location": {
            "contact": {
                "email": "lvsa@sina.com", 
                "last_name": "Sa Lv, MD", 
                "phone": "86-10-63879735", 
                "phone_ext": "2015.12"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100039"
                }, 
                "name": "Research Center for Biological Therapy, The Institute of Translational Hepatology, Beijing 302 Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B", 
        "overall_contact": {
            "email": "lvsa@sina.com", 
            "last_name": "Sa Lv, MD", 
            "phone": "86-10-63879735", 
            "phone_ext": "2014.12"
        }, 
        "overall_official": {
            "affiliation": "Beijing 302 Hospital", 
            "last_name": "Fu-Sheng Wang, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the rates of HBeAg seroconversion", 
            "safety_issue": "No", 
            "time_frame": "at week 72"
        }, 
        "reference": [
            {
                "PMID": "21423260", 
                "citation": "Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):275-84. doi: 10.1038/nrgastro.2011.33. Epub 2011 Mar 22. Review. PubMed PMID: 21423260."
            }, 
            {
                "PMID": "21978243", 
                "citation": "Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011 Nov;34(10):1145-58. doi: 10.1111/j.1365-2036.2011.04869.x. Epub 2011 Oct 7. Review."
            }, 
            {
                "PMID": "22541703", 
                "citation": "Kuo A, Gish R. Chronic hepatitis B infection. Clin Liver Dis. 2012 May;16(2):347-69. doi: 10.1016/j.cld.2012.03.003. Review."
            }, 
            {
                "PMID": "15738952", 
                "citation": "Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005 Mar;5(3):215-29. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01906580"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "normalisation of ALT", 
                "safety_issue": "No", 
                "time_frame": "at week 2\u30014\u300112\u300124\u300136\u300148\u300160\u300172\u300184\u300196"
            }, 
            {
                "measure": "liver histological improvement", 
                "safety_issue": "No", 
                "time_frame": "at baseline and at week 72"
            }, 
            {
                "measure": "The rates of HBsAg negative", 
                "safety_issue": "No", 
                "time_frame": "at week12\u300124\u300136\u300148\u300160\u300172\u300184\u300196"
            }, 
            {
                "measure": "the rate of virological response", 
                "safety_issue": "No", 
                "time_frame": "at week 4\u300112\u300124\u300136\u300148\u300160\u300172\u300184\u300196"
            }, 
            {
                "measure": "the rate of HBeAg negative", 
                "safety_issue": "No", 
                "time_frame": "at week 12\u300124\u300136\u300148\u300160\u300172\u300184\u300196"
            }
        ], 
        "source": "Beijing 302 Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing 302 Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}